Sushrusha Nayak
Sushrusha Nayak
Sobi, Karolinska Institute
Geverifieerd e-mailadres voor
Geciteerd door
Geciteerd door
Progress and prospects: immune responses to viral vectors
S Nayak, RW Herzog
Gene therapy 17 (3), 295-304, 2010
Induction and role of regulatory CD4+ CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer
O Cao, E Dobrzynski, L Wang, S Nayak, B Mingle, C Terhorst, RW Herzog
Blood 110 (4), 1132-1140, 2007
Glucose oxidation modulates anoikis and tumor metastasis
S Kamarajugadda, L Stemboroski, Q Cai, NE Simpson, S Nayak, M Tan, ...
Molecular and cellular biology 32 (10), 1893-1907, 2012
Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis
S Kamarajugadda, Q Cai, H Chen, S Nayak, J Zhu, M He, Y Jin, Y Zhang, ...
Cell death & disease 4 (2), e504, 2013
Pompe disease gene therapy
BJ Byrne, DJ Falk, CA Pacak, S Nayak, RW Herzog, ME Elder, SW Collins, ...
Human molecular genetics, ddr174, 2011
GITR engagement preferentially enhances proliferation of functionally competent CD4+ CD25+ FoxP3+ regulatory T cells
G Liao, S Nayak, JR Regueiro, SB Berger, C Detre, X Romero, ...
International immunology 22 (4), 259-270, 2010
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies
DM Markusic, BE Hoffman, GQ Perrin, S Nayak, X Wang, PA LoDuca, ...
EMBO molecular medicine 5 (11), 1698-1709, 2013
Induction of tolerance to factor VIII by transient co‐administration with rapamycin
B Moghimi, BK Sack, S Nayak, DM Markusic, CS Mah, RW Herzog
Journal of Thrombosis and Haemostasis 9 (8), 1524-1533, 2011
Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B
O Cao, BE Hoffman, B Moghimi, S Nayak, M Cooper, S Zhou, HCJ Ertl, ...
Molecular Therapy 17 (10), 1733-1742, 2009
Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer
M Cooper, S Nayak, BE Hoffman, C Terhorst, O Cao, RW Herzog
Human gene therapy 20 (7), 767-776, 2009
B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
M Corti, ME Elder, DJ Falk, L Lawson, BK Smith, S Nayak, TJ Conlon, ...
Molecular Therapy—Methods & Clinical Development 1, 2014
Sustained Correction of Motoneuron Histopathology Following Intramuscular Delivery of AAV in Pompe Mice
MK ElMallah, DJ Falk, S Nayak, RA Federico, MS Sandhu, A Poirier, ...
Molecular Therapy 22 (4), 702-712, 2014
B-Cell Depletion and Immunomodulation before Initiation of Enzyme Replacement Therapy Blocks the Immune Response to Acid Alpha-Glucosidase in Infantile-Onset Pompe Disease
ME Elder, S Nayak, SW Collins, LA Lawson, JS Kelley, RW Herzog, ...
The Journal of pediatrics 163 (3), 847-854. e1, 2013
Prophylactic immune tolerance induced by changing the ratio of antigen‐specific effector to regulatory T cells
S Nayak, O Cao, BE Hoffman, M Cooper, S Zhou, MA Atkinson, ...
Journal of Thrombosis and Haemostasis 7 (9), 1523-1532, 2009
Tolerance Induction to Cytoplasmic β-Galactosidase by Hepatic AAV Gene Transfer—Implications for Antigen Presentation and Immunotoxicity
AT Martino, S Nayak, BE Hoffman, M Cooper, G Liao, DM Markusic, ...
PloS one 4 (8), e6376, 2009
Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell–dependent induction of CD4+ CD25+ FoxP3+ Treg
M Biswas, D Sarkar, SRP Kumar, S Nayak, GL Rogers, DM Markusic, ...
Blood 125 (19), 2937-2947, 2015
Co-Packaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease
PA Doerfler, AG Todd, N Clement, D Falk, S Nayak, R Herzog, BJ Byrne
Human gene therapy, 2015
Targeted approaches to induce immune tolerance for Pompe disease therapy
PA Doerfler, S Nayak, M Corti, L Morel, RW Herzog, BJ Byrne
Molecular therapy. Methods & clinical development 3, 15053, 2016
Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B
S Nayak, D Sarkar, GQ Perrin, B Moghimi, BE Hoffman, S Zhou, BJ Byrne, ...
Frontiers in microbiology 2, 2011
Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent
S Nayak, PA Doerfler, SL Porvasnik, DD Cloutier, R Khanna, ...
PloS one 9 (6), e98336, 2014
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20